{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:45:37Z","timestamp":1784169937726,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.atherosclerosis.2013.10.022","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T18:38:15Z","timestamp":1383331095000},"page":"86-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20\u00a0mg plus ezetimibe 10\u00a0mg vs. simvastatin 40 or 80\u00a0mg plus ezetimibe 10\u00a0mg in high-risk patients: Results of the GRAVITY randomized study"],"prefix":"10.1016","volume":"232","author":[{"given":"Christie M.","family":"Ballantyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron C.","family":"Hoogeveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe L.","family":"Raya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie A.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike K.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn W.","family":"Karlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib1","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jchromb.2010.06.010","article-title":"Quantitative analysis of five sterols in amniotic fluid by GC-MS: application to the diagnosis of cholesterol biosynthesis defects","volume":"878","author":"Amaral","year":"2010","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.freeradbiomed.2006.12.013","article-title":"Increased plasma levels of oxysterols, in\u00a0vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy","volume":"42","author":"Arca","year":"2007","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib3","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40\u00a0mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjcard.2011.03.079","article-title":"Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10\u00a0mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE study)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J\u00a0Roy Statist Soc Ser B (Methodological)"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2362.2007.01808.x","article-title":"Age-related changes in bile acid synthesis and hepatic nuclear receptor expression","volume":"37","author":"Bertolotti","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (IMProved reduction of outcomes: vytorin efficacy international trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","volume":"156","author":"Cannon","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib9","first-page":"949672","article-title":"The role of bile acid excretion in atherosclerotic coronary artery disease","volume":"2012","author":"Charach","year":"2012","journal-title":"Int J Vasc Med"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/abio.1995.1110","article-title":"Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry","volume":"225","author":"Dzeletovic","year":"1995","journal-title":"Anal Biochem"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1742-1241.2009.02022.x","article-title":"Lipid-altering efficacy of ezetimibe\/simvastatin 10\/20\u00a0mg compared with rosuvastatin 10\u00a0mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy \u2013 the IN-CROSS study","volume":"63","author":"Farnier","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib12","series-title":"FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury","year":"2011"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2004.11.007","article-title":"Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins","volume":"180","author":"Geiss","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5551\/jat.No703","article-title":"Clinical significance of serum 7-ketocholesterol concentrations in the progression of coronary atherosclerosis","volume":"16","author":"Hitsumoto","year":"2009","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib16","first-page":"e261","article-title":"Relationship between circulating levels of oxysterols and carotid artery characteristics: the ARIC carotid MRI study","volume":"30","author":"Hoogeveen","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1194\/jlr.M001487","article-title":"Baseline cholesterol absorption and the repose to ezetimibe\/simvastatin therapy: a post-hoc analysis of the ENHANCE trial","volume":"51","author":"Jakulj","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib20","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1194\/jlr.M200071-JLR200","article-title":"Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain","volume":"43","author":"Lutjohann","year":"2002","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/clc.20853","article-title":"The effects of statin monotherapy and low-dose statin\/ezetimibe on lipoprotein-associated phospholipase A2","volume":"34","author":"Lee","year":"2011","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib22","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1046\/j.1365-2362.1999.00475.x","article-title":"Effect of inhibiting HMG-CoA reductase on 7 alpha-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway","volume":"29","author":"Naoumova","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5551\/jat.1651","article-title":"Effects of ezetimibe on remnant-like\u00a0partical cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia","volume":"17","author":"Nozue","year":"2010","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1073\/pnas.0807675106","article-title":"Dual biosynthetic pathways to phytosterol via cycloartenol and lanosterol in arabidopsis","volume":"106","author":"Ohyama","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib25","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib26","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1161\/ATVBAHA.107.147280","article-title":"Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2","volume":"27","author":"Saougos","year":"2007","journal-title":"Aterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib27","first-page":"357","article-title":"Very low levels of HDL cholesterol and atherosclerosis, a variable relationship\u2013a review of LCAT deficiency","volume":"8","author":"Savel","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib28","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S1734-1140(11)70698-3","article-title":"Ezetimibe \u2013 a new approach in hypercholesterolemia management","volume":"63","author":"Suchy","year":"2011","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality","volume":"302","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2013.10.022_bib31","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80\u00a0mg versus 20\u00a0mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","year":"2010","journal-title":"Lancet"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915013006229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915013006229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T05:40:45Z","timestamp":1716097245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915013006229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0021915013006229"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.10.022","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20\u00a0mg plus ezetimibe 10\u00a0mg vs. simvastatin 40 or 80\u00a0mg plus ezetimibe 10\u00a0mg in high-risk patients: Results of the GRAVITY randomized study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}